Loading...
The Highest Mountain - T-Cell Technology
McIntosh, Bryan Fascia, M.
McIntosh, Bryan
Fascia, M.
Publication Date
2014
End of Embargo
Supervisor
Rights
� 2014 MA Healthcare Ltd. Full-text reproduced in accordance with the publisher's self-archiving policy.
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
T-lymphocytes (T-cell) therapy offers a treatment for cancers. Developing this technology in the future provides the opportunity to revolutionise treatment and to make cancer a chronic condition. T-cells in themselves are a type of lymphocytes (itself a type of white blood cell) that play a central role in cell mediated immunity. They can be distinguished from other lymphocytes, such as B-cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on the cell surface. T-cells have the capacity to destroy diseased cells, but tumours present a considerable challenge that reduces their impact. As cancer cells are frequently ‘invisible’ to the immune system, and they create an environment that suppresses T-cell activity., genetic engineering of T-cells can be used therapeutically to overcome these challenges. T-cells can be taken from the blood of cancer patients and then modified to recognise and destroy cancer-specific antigens.
Version
Accepted manuscript
Citation
McIntosh B and Fascia M (2014) The Highest Mountain: T- Cell Technology. British Journal of Healthcare Management. 20(6): 281-285.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article